05:25 PM EDT, 07/23/2025 (MT Newswires) -- Viking Therapeutics ( VKTX ) reported Q2 loss late Wednesday of $0.58 per diluted share, widening from $0.20 a year earlier.

Analysts polled by FactSet expected a loss of $0.45.

As expected, no revenue for the quarter ended June 30 was reported.

As of June 30, the company said it had $808 million in cash and or cash equivalents on hand, and expected it could fund the advancement of the VK2735 program for obesity through phase 3 trials.

Shares were down 6.5% during after-hours trading.